目的:探讨临床常见恶性肿瘤患者血清细胞质胸苷激酶(TK1)的应用价值。方法:利用免疫印迹增强化学发光法,测定230例肿瘤患者和161例健康体检者血清中的TK1水平,进行对照研究。结果:健康体检者血清TK1阳性率为6.21%,鳞癌患者TK1阳性率为29.41%,腺癌患者TK1阳性率为46.58%。其中宫颈癌、肺癌、子宫肌瘤TK1阳性率较低,阳性率分别为25%,22%,而肝癌、胃癌、直肠癌、乳腺癌TK1阳性率较高,阳性率分别为70%,61.54%,54.55%,50%。结论:血清TK1检测在肿瘤的早期发现、治疗评估、预后判断、以及组织分型等方面都具有重要作用。 Objective: To investigate the clinical value of serum cytoplasmic thymidine kinase (TK1) in patients with common malignant tumors. Methods: Immunofluorescence staining was used to determine the level of TK1 in serum of 230 cancer patients and 161 healthy subjects, and the control study was conducted. Results: The positive rate of TK1 in healthy subjects was 6.21%, the positive rate of TK1 in squamous cell carcinoma was 29.41%, and the positive rate of TK1 in adenocarcinoma was 46.58%. The positive rates of TK1 in cervical cancer, lung cancer and uterine fibroids were lower, with the positive rates of 25% and 22%, respectively. The positive rates of TK1 in liver cancer, gastric cancer, rectal cancer and breast cancer were higher, with the positive rates of 70% and 61.54% , 54.55%, 50%. Conclusion: The detection of serum TK1 plays an important role in the early detection of tumor, evaluation of treatment, prognosis judgment and tissue typing.